– Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, I Lim JI, Vemulakonda GA, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020;127:P66–P145.
– Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237:185–222.
1. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001;44:156–63.
2. Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64:631–42.
3. XieX, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet. 2016;387:435–43.
4. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:17.
5. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–64.
6. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch. Ophthalmol. 1984;102:520–6.
7. Varma R, Torres M, Peña F, Klein R, Azen SP. Prevalence of diabetic retinopathy in adult Latinos: The Los Angeles Latino eye study. Ophthalmology. 2004;111:1298–1306.
8. American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62–9.
9. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 2005;54:1615–25.
10. Bek T. Diameter changes of retinal vessels in diabetic retinopathy. Curr Diab Rep. 2017:17:82.
11. Ejaz S, Chekarova I, Ejaz A, Sohail A, Lim CW. Importance of pericytes and mechanisms of pericyte loss during diabetes retinopathy. Diabetes Obes Metab. 2008;10:53–63.
12. Beltramo E, Porta M. Pericyte loss in diabetic retinopathy: Mechanisms and consequences. Curr Med Chem. 2013;20:3218–25.
13. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishiet S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001:15:257–9.
14. Schröder S, Palinski W, Schmid-Schönbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991:139:81–100.
15. Joussen A, Poulaki V, Mitsiades N, Cai W, Suzuma I, Pak J, et al. Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2003;17:76–8.
16. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991;98:786–806.
17. Lois N, McCarter RV, O’Neill C, Medina RJ, Stitt AW. Endothelial progenitor cells in diabetic retinopathy. Front Endocrinol (Lausanne). 2014;5:44.
18. Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey l, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020;34:1–51.
19. Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkinset A, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016:51:156–86.
20. Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Yinget GS, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology.2020;127: P66–P145.
21. Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol. 1995;113:1144–55.
22. Yannuzzi LA, Rohrer KT, Tindel LJ, Sobel RS, Costanza MA, Shields W, Zang E, et al. Fluorescein angiography complication survey. Ophthalmology. 1986;93:611–7.
23. Sikorski BL, Malukiewicz G, Stafiej J, Lesiewska-Junk H, Raczynska D. The diagnostic function of OCT in diabetic maculopathy. Mediators Inflamm. 2013; 434560.
24. Tey KY, Teo K, Tan ACS, Devarajan K, Tan B, Tan J, et al. Optical coherence tomography angiography in diabetic retinopathy: A review of current applications. Eye Vis. 2019;6:37.
25. Lueder GT, Silverstein J, et al. Screening for retinopathy in the pediatric patient with type 1 diabetes mellitus. Pediatrics. 2005;116:270–3.
26. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy: III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984;102:527–32.
27. Nathan DM, Chew E, Christophi CA, Davis MD, Fowler S, Goldstein BJ, et al. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabetes UK. Diabet Med. 2007;24:137–4.
28. Gunderson EP, Lewis CE, Tsai AL, Chiang V, Carnethon M, Quesenberry Jr CP and Sidney S, et al. A 20-year prospective study of childbearing and incidence of diabetes in young women, controlling for glycemia before conception: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Diabetes. 2007;56, 2990–6.
29. Klein BEK, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13:34–40.
30. Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.
31. The Diabetes Control and Complications Trial (DCCT). The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–83.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–13.
33. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology. 1998;105: 1801–15.
34. Hammer SS, Busik JV. The role of dyslipidemia in diabetic retinopathy. Vision Res. 2017;139:228–36.
35. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol. 1976;81:397–402.
36. Vail D. Light Coagulation. Am J Ophthalmol. 1961;51:724–5.
37. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766–85.
38. Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feineret L, et al. Ranibizumab for diabetic macular edema: Results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801.
39. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U4, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID Studies. Ophthalmology. 2016;123:2376–85.
40. Sachdeva MM, Moshiri A, Leder HA, Scott AW. Endophthalmitis following intravitreal injection of anti-VEGF agents: Long-term outcomes and the identification of unusual micro-organisms. J Ophthalmic Inflamm Infect. 2016;6:2.
41. Guigou S, Hajjar C, Parrat E, Merite PY, Pommier S, Matont F, et al. [Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study]. J Fr Ophtalmol. 2014;37:480–5.
42. Schmitz K, Maier M, Clemens CR, Höhn F, Wachtlin J, Lehmann F, et al. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study]. Ophthalmologe. 2014;111:44–52.
43. Stewart MW, Browning DJ, Landers MB. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018;66:1751–62.